Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bellera

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2013
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative StudyA Italiano, A Le Cesne, C Bellera, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2018
Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international surveyE Paillaud, P Soubeyran, P Caillet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2013
Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based studyS Mathoulin-Pélissier, C Chevreau, C Bellera, et al.
Nature Medicine|May 26, 2022
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohortA Italiano, A Bessede, M Pulido, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2013
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative StudyA Italiano, A Le Cesne, C Bellera, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2018
Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international surveyE Paillaud, P Soubeyran, P Caillet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2013
Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based studyS Mathoulin-Pélissier, C Chevreau, C Bellera, et al.
Nature Medicine|May 26, 2022
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohortA Italiano, A Bessede, M Pulido, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2022
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)A Bayle, F Peyraud, L Belcaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 2